Theoretical relationship of lung deposition to the fine particle fraction of inhalation aerosols

Pharmaceutica Acta Helvetiae

Volumn 71, Issue 3, 1996, Pages 185-190

  Hickey, Anthony J ^a   Martonen, Ted B ^b   Yang, Yadong ^c  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Inertial impaction; Inhalation aerosol; Lung deposition

Indexed keywords

AEROSOL; ARTICLE; INHALATION; LUNG DEPOSIT; MATHEMATICAL MODEL; THEORY;

EID: 0030217972     PISSN: 00316865     EISSN: None     Source Type: Journal    
DOI: 10.1016/0031-6865(96)00014-3     Document Type: Article

References (30)

1. [1] Aerosols 601 (1992), in USP XXII. 7th Supplement, pp. 3123-3129.
2. [2] British Pharmacopoeia (1988), Vol II Appendix XVIIB, HMSO, London, pp. A204-A207.
3. [3] Chowhan, Z.T., Casey, D.L., Byron, P.R., Kelly, E.L., Chaudry, I., Lovering, E.G., Vadas, E., and Thiel, C.G. (1991) Recommendations of the USP Advisory Panel on Aerosols. Pharm. Forum. 17, 1703-1713.
4. [4] Cipolla, D.C., Clark, A.R., Chan, H.-K., Gonda, I., and Shire, S.J. (1994) Assessment of aerosol delivery systems for recombinant human deoxyribonuclease. STP Pharma Sciences, 4, 50-62.
5. [5] Clark, A.R. and Egan, M. (1994) Modelling the deposition of inhaled powder drug aerosols, J. Aerosol Sci., 25, 175-186.
6. [6] Clark, A.R. and Hollingworth (1993) The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers - implications for in vivo testing. J. Aerosol Med., 6, 99-110.
7. [7] Dolovich, M. (1993) Lung dose, distribution, and clinical response to therapeutic aerosols. Aerosol Sci. Tech., 18, 230-240.
8. [8] Heyder, J., Gebhart, J., Rudolph, G., Schiller, C.F., and Stahlhofen, W. (1986) Deposition of particles in the human respiratory tract in the size range 0.005-15 μm. J. Aerosol Sci., 17, 811-825.
9. [9] Hickey, A.J. (1992) Methods of Aerosol Particle Size Characterization, in Pharmaceutical Inhalation Aerosol Technology, Hickey A.J., Ed., Marcel Dekker, New York, NY, pp. 219-253.
10. [10] Hickey, A.J. (1990) Factors influencing aerosol deposition in inertial impactors and their effect on particle size characterization. Pharm. Tech., 14, 118-130.
11. [11] Hickey, A.J. and Fults, K. Correlation of estimated respirable fraction of an aerosol with theoretical lung deposition. (1991) Pharm Res., 8, S6.
12. [12] Hinds, W.C. (1982), in Aerosol Technology, Properties, Behavior and Measurement of Airborne Particles, John Wiley and Sons, New York, NY. pp. 211-232.
13. [13] Leong, K.H. (1992) Theoretical Principles and Devices Used to Generate Aerosols for Research, in Pharmaceutical Inhalation Aerosol Technology, Hickey, A.J., Ed., Marcel Dekker, New York, NY, pp. 129-154.
14. [14] Martonen, T.B. (1983a) On the fate of inhaled particles in the human: a comparison of experimental data with theoretical computations based on a symmetric and asymmetric lung. Bull. Math. Biol., 45, 409-424.
15. [15] Martonen, T. (1983b) Deposition of inhaled particulate matter in the upper respiratory tract, larynx, and bronchial airways: a mathematical description. J. Toxicol. Environ. Health, 12, 787-800.
16. [16] Martonen, T.B. (1993) Mathematical model for the selective deposition of inhaled pharmaceuticals. J. Pharm. Sci., 82, 1191-1199.
17. [17] Martonen, T.B. (1982) Analytical model of hygroscopic particle behavior in human airways. Bull. Math. Biol., 44, 425-442.
18. [18] Martonen, T.B. and Katz, I. (1994) Inter-related effects of morphology and ventilation on drug deposition patterns. S.T.P. Pharma. Sci., 4, 11-18.
19. [19] Martonen, T.B., and Katz, I. (1993a) Deposition patterns of aerosolized drugs within human lungs: effects of ventilatory parameters. Pharm. Res., 10, 871-878.
20. [20] Martonen, T.B., and Katz, I. (1993b) Deposition patterns of polydisperse aerosols within human lungs, J. Aerosol Med., 6, 251-274.
21. [21] Martonen, T.B., Graham, R.C., and Hofmann, W. (1989) Human subject age and and activity level: factors addressed in biomathematical deposition program for extrapolation modeling. Health Physics, 57, 49-59.
22. [22] Martonen, T.B., Hofmann, Eisner, A.D., and Menache, M.G. (1989) in Extrapolation of Dosimetric Relationships for Inhaled Particles and Gases. Crapo, J.D.; Smolko, E.D.; Miller, F.J.; Graham, J.A.; and Wallace A.W., Eds., Academic Press, San Diego, pp. 303-316.
23. [23] Martonen, T.B., Katz, I., Fults, K., and Hickey, A.J. (1992) Use of analytically defined estimales of aerosol respirable fraction to predict lung deposition patterns. Pharm. Res., 9, 1634-1639.
24. [24] Mercer, T.T. (1973), in Aerosol Technology in Hazard Evaluation, Academic Press, New York, NY, pp. 284-293.
25. [25] Newman, S.P., Moren, F., Trofast, E., Talee, N., and Clarke, S.W. (1989) Deposition and clinical efficacy of terbutaline sulphate from Turbuhaler, a new multi-dose powder inhaler. Eur. Respir. J., 2, 247-251.
26. [26] Newman, S.P., Weisz, A.W.B., Talee, N., and Clarke, S.W. (1991) Improvement of drug delivery with a breath actuated pressurized aerosol for patients with poor inhaler technique. Thorax. 46, 712-716.
27. [27] Raabe, O.G. (1971) Particle size analysis utilizing grouped data and the log-normal distribution. J. Aerosol Sci., 2. 289-303.
28. [28] Stahlhofen, W., Rudolf, G., and James, A.C. (1989) Intercomparison of experimental regional aerosol deposition data. J. Aerosol Med., 2. 285-308
29. [29] Task Group on Lung Dynamics, ICRP Committee 2 (1966) Deposition and retention models for internal dosimetry of the human respiratory tract. Health Physics, 12, 173-207.
30. [30] Weibel, E.R. (1963) Morphometry of the Human Lung, Academic Press. New York, NY.